European Registry of Transcatheter Repair for Tricuspid Regurgitation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLMU Klinikum
About this trial
To investigate clinical and survival outcomes following transcatheter tricuspid valve repair or replacement.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients treated with one of the following transcatheter devices for TV repair or replacement: PASCAL, TriClip, TricValve, Evoque, LuX-Valve
Age ≥ 18 years
Disqualifiers
None
Trial population
Patients treated with one of the following transcatheter devices for TV repair or replacement (e.g. PASCAL, TriClip, TricValve, Evoque, LuX-Valve)
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
T-TEER
DeviceT-TEER using the PACAL or TriClip device
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
All-cause mortality
Time frame
5 yearsSecondary outcomes
1
Technical success
absence of procedural mortality, successful access, delivery and retrieval of the delivery system, successful deployment and positioning, freedom from emergency surgery
Time frame
5 years2
Procedural Safety
periprocedural and in-hospital adverse events
Time frame
5 years3
Heart Failure Biomarker
NT-proBNP level
Time frame
5 years4
Dyspnea on exertion
New York Heart Association (NYHA) functional class
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov